SEMA3A: A Potential Drug Target and Biomarker (G10371)

Target Name: SEMA3A

NCBI ID: G10371

SEMA3A

SEMA3A: A Potential Drug Target and Biomarker

SEMA3A, short for solute carrier family 3 member A, is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell signaling, specifically in the regulation of angiogenesis, which is the process by which new blood vessels are formed. SEMA3A plays a crucial role in the formation of blood vessels and has been implicated in several diseases, including cardiovascular disease and cancer. As a result, SEMA3A has become a focus of interest for researchers as a potential drug target and biomarker.

The SEMAD gene is located on chromosome 12q14 and encodes a protein that is composed of 216 amino acids. SEMA3A is expressed in various tissues, including the brain, heart, kidneys, and intestines. It is highly conserved across species, with only minor differences in its sequence. SEMA3A is involved in the regulation of cell signaling, specifically in the regulation of angiogenesis.

SEMA3A is a key regulator of angiogenesis, as it plays a critical role in the formation of blood vessels. During angiogenesis, SEMA3A helps to regulate the growth and differentiation of new blood vessels, ensuring that they have the necessary structure and function to carry oxygen and nutrients to the growing body. SEMA3A is also involved in the regulation of the destruction of blood vessels, which is important for maintaining blood pressure and cardiovascular health.

SEMA3A has been implicated in several diseases, including cardiovascular disease and cancer. For example, studies have shown that SEMA3A is significantly over-expressed in the brains of patients with Alzheimer's disease, a progressive neurodegenerative disorder. Additionally, SEMA3A has been shown to be involved in the regulation of cancer cell growth and angiogenesis, which may contribute to its role in the development of cancer.

As a result, SEMA3A has become a focus of interest for researchers as a potential drug target and biomarker. Researchers are actively searching for small molecules that can inhibit SEMA3A's activity, with the goal of developing new treatments for cardiovascular disease and cancer. SEMA3A has also been shown to interact with several other proteins, including NF-kappa1, a key regulator of angiogenesis. This suggests that inhibiting SEMA3A's activity with small molecules that interact with NF-kappa1 may be an effective way to target its role in the regulation of angiogenesis.

In addition to its potential as a drug target, SEMA3A has also been shown to be a potential biomarker for several diseases. For example, SEMA3A has been shown to be involved in the regulation of blood pressure, which is an important predictor of cardiovascular disease. Additionally, SEMA3A has been shown to be involved in the regulation of inflammation, which is a key factor in the development of many diseases, including cardiovascular disease and cancer. As a result, SEMA3A has the potential to serve as a biomarker for these diseases, as well as others that are related to its role in cell signaling.

In conclusion, SEMA3A is a protein that is involved in the regulation of cell signaling, specifically in the regulation of angiogenesis. Its role in the formation of blood vessels and its involvement in the regulation of angiogenesis make it a potential drug target and biomarker. Further research is needed to fully understand the role of SEMA3A in the regulation of angiogenesis and its potential as a drug target and biomarker.

Protein Name: Semaphorin 3A

Functions: Involved in the development of the olfactory system and in neuronal control of puberty. Induces the collapse and paralysis of neuronal growth cones. Could serve as a ligand that guides specific growth cones by a motility-inhibiting mechanism. Binds to the complex neuropilin-1/plexin-1

The "SEMA3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEMA3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets